---
title: "Salarius Pharmaceuticals (SLRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SLRX.US.md"
symbol: "SLRX.US"
name: "Salarius Pharmaceuticals"
industry: "Biotechnology"
datetime: "2026-05-21T17:29:33.673Z"
locales:
  - [en](https://longbridge.com/en/quote/SLRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SLRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SLRX.US.md)
---

# Salarius Pharmaceuticals (SLRX.US)

## Company Overview

Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.07 | 201 | - | - | - |
| PB | 1.26 | 105 | 24.07 | 1.26 | 1.26 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2024-09-09T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.84 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SLRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SLRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SLRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SLRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**